These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 20643572)
21. Antibody-drug conjugates as targeted cancer therapeutics. Sun Y; Yu F; Sun BW Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167 [TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Peters C; Brown S Biosci Rep; 2015 Jun; 35(4):. PubMed ID: 26182432 [TBL] [Abstract][Full Text] [Related]
23. Antibody-drug conjugates for cancer: poised to deliver? Hughes B Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367 [No Abstract] [Full Text] [Related]
24. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance]. Chen JN; Shen Q; Li SS Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047 [TBL] [Abstract][Full Text] [Related]
25. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Robak T; Robak E Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159 [TBL] [Abstract][Full Text] [Related]
26. Inotuzumab ozogamicin as novel therapy in lymphomas. Wong BY; Dang NH Expert Opin Biol Ther; 2010 Aug; 10(8):1251-8. PubMed ID: 20528256 [TBL] [Abstract][Full Text] [Related]
27. CD70 as a therapeutic target in human malignancies. Grewal IS Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343 [TBL] [Abstract][Full Text] [Related]
28. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951 [TBL] [Abstract][Full Text] [Related]